- Home
- SPPL vs ADXN Comparison
SPPL vs ADXN Comparison
Compare SPPL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- ADXN
- Stock Information
- Founded
- SPPL 2016
- ADXN 2002
- Country
- SPPL Singapore
- ADXN Switzerland
- Employees
- SPPL N/A
- ADXN N/A
- Industry
- SPPL
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- ADXN Health Care
- Exchange
- SPPL Nasdaq
- ADXN Nasdaq
- Market Cap
- SPPL 9.8M
- ADXN 10.1M
- IPO Year
- SPPL 2023
- ADXN N/A
- Fundamental
- Price
- SPPL $3.38
- ADXN $7.94
- Analyst Decision
- SPPL
- ADXN Strong Buy
- Analyst Count
- SPPL 0
- ADXN 1
- Target Price
- SPPL N/A
- ADXN $30.00
- AVG Volume (30 Days)
- SPPL 31.1K
- ADXN 1.5K
- Earning Date
- SPPL 01-01-0001
- ADXN 09-01-2025
- Dividend Yield
- SPPL N/A
- ADXN N/A
- EPS Growth
- SPPL N/A
- ADXN N/A
- EPS
- SPPL N/A
- ADXN 0.10
- Revenue
- SPPL $2,764,846.00
- ADXN $278,508.00
- Revenue This Year
- SPPL N/A
- ADXN $86.57
- Revenue Next Year
- SPPL N/A
- ADXN N/A
- P/E Ratio
- SPPL N/A
- ADXN $0.69
- Revenue Growth
- SPPL N/A
- ADXN N/A
- 52 Week Low
- SPPL $2.16
- ADXN $6.51
- 52 Week High
- SPPL $16.80
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- SPPL 57.65
- ADXN 45.33
- Support Level
- SPPL $2.50
- ADXN $7.52
- Resistance Level
- SPPL $3.00
- ADXN $8.21
- Average True Range (ATR)
- SPPL 0.33
- ADXN 0.10
- MACD
- SPPL 0.01
- ADXN -0.03
- Stochastic Oscillator
- SPPL 73.34
- ADXN 50.00
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.